All In Biotech

Drug Trial Radar · NCT07864701

Study of JMBI-001 in Patients With MYC-Positive Advanced Cancers

A Phase I/II Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity and Efficacy of JMBI-001 Tablets in Participants With MYC-Positive Advanced Solid Tumors or Relapsed/Refractory Non-Hodgkin Lymphoma

Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Oct 2026

Primary completion

Jun 2029

Study completion Jun 2030

Sponsor

Sponsor type
Industry
Collaborators
Peking University Cancer Hospital & Institute
First posted
Oct 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluate the safety and tolerability of JMBI-001 in adults with MYC-positive advanced cancers.

Conditions

  • Advance Solid Tumors
  • Lymphoma, Non-Hodgkin

Interventions

  • JMBI-001 TabletsDrug

    JMBI-001 will be administered orally once daily on an empty stomach for 4 consecutive days, followed by 3 days without treatment, in repeated 21-day treatment cycles. Dose levels will be determined according to the study protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ia: dose-limiting toxicities (DLTs)Time frame: Cycle 1, Days 1-21 after the first dose (21-day DLT assessment period)
  2. Phase Ia: maximum tolerated dose (MTD)Time frame: At completion of Phase Ia dose escalation, after completion of the 21-day DLT assessment period for each dose cohort, up to approximately 15 months after the first participant receives the first dose.
  3. Phase 1a:recommended dose for expansion (RDE)Time frame: At completion of Phase Ia dose escalation, after review of DLTs and other available safety data, up to approximately 15 months after the first participant receives the first dose.
  4. Phase Ia/Ib: adverse events (AEs), serious adverse events (SAEs)Time frame: From informed consent, during each 21-day treatment cycle, at the end-of-treatment visit (within 7 days of treatment discontinuation), and through 30 days after the last dose or until new anticancer therapy starts, whichever occurs first
  5. Phase Ib: determination of the recommended Phase II dose (RP2D)Time frame: From the first dose administered to the first participant in Phase Ia through completion of Phase Ib dose expansion, up to approximately 27 months.
  6. Phase II: Objective response rate (ORR)Time frame: From baseline until disease progression, initiation of new anticancer therapy, or withdrawal, assessed up to approximately 24 months.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University Cancer Hospital & Institute

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.